NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BlossomHill Therapeutics

BlossomHill Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://bhtherapeutics.com/

Last Round

Series B

Extension

Dec 10, 2025

Total Funding Raised

$343.65M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

BlossomHill Therapeutics is a biopharmaceutical company that discovers and develops small molecule medicines for the treatment of high-need cancers and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalsmall molecule therapeuticsoncologymacrocyclic chemistrydrug discoverynon-small cell lung cancerNSCLCEGFR-mutantKRAS inhibitorclinical trialsbiotechdrug pipelinecancer researchmedicinal chemistryclinical-stage

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BlossomHill Therapeutics Comps

Public and private peers based on sector, stage, and business model.

BlossomHill Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

BlossomHill Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionDec 10, 2025
Series BFeb 29, 2024
Series BDec 28, 2023
Series AMar 3, 2021

Key People

Founding team and executive leadership

J. Jean Cui

Scientific Founder, President And CEO

Founding Team

Jason Keyes

Chief Financial Officer

Executive Team

BlossomHill Therapeutics Investors

Notable investors and investment history

BlossomHill Therapeutics investors
InvestorRounds
BioTrack CapitalSeries B Extension
Janus Henderson GroupSeries B Extension
H&D Asset ManagementSeries B
Cormorant Asset ManagementSeries B, Series B Extension, Series A
OrbiMedSeries B, Series B Extension, Series A
Brahma CapitalSeries B Extension
Plaisance Capital ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 30, 2026

    Grew 17% QoQ, from 59 to 69 employees.

  • Apr 21, 2026

    Presented at the Mini Symposium at AACR 2026.

BlossomHill Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BlossomHill Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BlossomHill Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range69
Year Founded2020
Last FundingDec 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.